{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T14:51:40Z","timestamp":1777560700275,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T00:00:00Z","timestamp":1587772800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T00:00:00Z","timestamp":1587772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Health Commission of Jinshan district, Shanghai","award":["JSKJ-KTMS-2019-17"],"award-info":[{"award-number":["JSKJ-KTMS-2019-17"]}]},{"DOI":"10.13039\/501100013088","name":"Qinglan Project of Jiangsu Province of China","doi-asserted-by":"crossref","award":["2018-JSYYQH-05"],"award-info":[{"award-number":["2018-JSYYQH-05"]}],"id":[{"id":"10.13039\/501100013088","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Statin remains a mainstay in the prevention and treatment of cardiovascular diseases. Statin utilization has evolved over time in many countries, but data on this topic from China are quite limited. This study aimed to investigate the changing trends of statins prescription, as well as detail the statin utilization through a successive longitudinal study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The prescription database was established based on electronic health records retrieved from the hospital information system of Jinshan Hospital, Fudan University from January 2012 to December 2018 in Shanghai, China. The prescription rates and proportions of different statin types and doses among all patients were examined. Sub-analyses were performed when stratifying the patients by age, gender, dose intensity, and preventative intervention.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>During the study period, a total of 51,083 patients, who were prescribed for statins, were included in this study (mean [SD] age, 59.78 [\u00b113.16] years; 53.60% male, <jats:italic>n<\/jats:italic>\u00a0=\u200927, 378). The overall statins prescription rate in which patients increased from 2012 (1.24, 95% CI: 1.21-1.27%) to 2018 (3.16, 95% CI: 3.11\u20133.20%), <jats:italic>P<\/jats:italic>\u00a0&lt;\u20090.001. Over 90% of patients were given a moderate dose of statins. Patients with a history of coronary and cerebrovascular events (over 32%) were more likely to be prescribed with statins for preventative intervention. Furthermore, our study has witnessed a significant rise in statin therapy in primary and secondary prevention.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In conclusion, statins were frequently prescribed and steadily increased over time in our study period. There were also changes in statin drug choices and dosages. A coordinated effort among the patient, clinical pharmacist, stakeholders and health system is still needed to improve statin utilization in clinical practice in the future.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-020-01482-5","type":"journal-article","created":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T18:03:33Z","timestamp":1587837813000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Time trends analysis of statin prescription prevalence, therapy initiation, dose intensity, and utilization from the hospital information system of Jinshan Hospital, Shanghai (2012\u20132018)"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1172-4886","authenticated-orcid":false,"given":"Yujuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqun","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhonghong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weifang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,25]]},"reference":[{"key":"1482_CR1","doi-asserted-by":"publisher","unstructured":"Sun W, Zhou Y, Zhang Z, Cao L, Chen W. The Trends in Cardiovascular Diseases and Respiratory Diseases Mortality in Urban and Rural China, 1990-2015. Int J Environ Res Public Health. 2017;14(11):1391. https:\/\/doi.org\/10.3390\/ijerph14111391.","DOI":"10.3390\/ijerph14111391"},{"issue":"4","key":"1482_CR2","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.jacl.2018.03.084","volume":"12","author":"JL Anderson","year":"2018","unstructured":"Anderson JL, Knowlton KU, May HT, Bair TL, Armstrong SO, Lappe DL, Muhlestein JB. Temporal changes in statin prescription and intensity at discharge and impact on outcomes in patients with newly diagnosed atherosclerotic cardiovascular disease-Real-world experience within a large integrated health care system: The IMPRES study. J Clin Lipidol. 2018;12(4):1008\u201318 e1001.","journal-title":"J Clin Lipidol"},{"issue":"2","key":"1482_CR3","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jacc.2015.05.030","volume":"66","author":"BJ Hirsh","year":"2015","unstructured":"Hirsh BJ, Smilowitz NR, Rosenson RS, Fuster V, Sperling LS. Utilization of and adherence to guideline-recommended lipid-lowering therapy after acute coronary syndrome: opportunities for improvement. J Am Coll Cardiol. 2015;66(2):184\u201392.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1482_CR4","first-page":"129","volume":"98","author":"W Tungsubutra","year":"2015","unstructured":"Tungsubutra W, Phongtuntakul B. Achievement of LDL-cholesterol goal with statins after an st segment elevation myocardial infarction. J Med Assoc Thail. 2015;98(2):129\u201336.","journal-title":"J Med Assoc Thail"},{"issue":"1","key":"1482_CR5","first-page":"7","volume":"2","author":"SP Zhao","year":"2016","unstructured":"Zhao SP. Amendment of the low-density lipoprotein cholesterol target in the \u2018Chinese guidelines for the prevention and treatment of adult dyslipidemia\u2019: opinion. Chron Dis Transl Med. 2016;2(1):7\u20139.","journal-title":"Chron Dis Transl Med"},{"issue":"7","key":"1482_CR6","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/j.1875-9114.2011.01086.x","volume":"32","author":"EM Heintjes","year":"2012","unstructured":"Heintjes EM, Penning-van Beest FJ, Plat AW, Meerding WJ, Webb K, Sturkenboom MC, Herings RM. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice. Pharmacotherapy. 2012;32(7):631\u201341.","journal-title":"Pharmacotherapy"},{"issue":"25 Suppl 2","key":"1482_CR7","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","volume":"129","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines. Circulation. 2014;129(25 Suppl 2):S1\u201345.","journal-title":"Circulation"},{"issue":"3","key":"1482_CR8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jsha.2014.09.004","volume":"27","author":"D Mahmood","year":"2015","unstructured":"Mahmood D, Jahan K, Habibullah K. Primary prevention with statins in cardiovascular diseases: a Saudi Arabian perspective. J Saudi Heart Assoc. 2015;27(3):179\u201391.","journal-title":"J Saudi Heart Assoc"},{"issue":"1","key":"1482_CR9","first-page":"1","volume":"15","author":"JR Zhu","year":"2018","unstructured":"Zhu JR, Gao RL, Zhao SP, Guoping LU, Zhao D, Jianjun LI, et al. 2016 Chinese guidelines for the management of dyslipidemia in adults. J Geriatr Cardiol Jgc. 2018;15(1):1\u201329.","journal-title":"J Geriatr Cardiol Jgc"},{"issue":"1","key":"1482_CR10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jamacardio.2016.4700","volume":"2","author":"JA Salami","year":"2017","unstructured":"Salami JA, Warraich H, Valero-Elizondo J, Spatz ES, Desai NR, Rana JS, et al. National Trends in statin use and expenditures in the US adult population from 2002 to 2013: insights from the medical expenditure panel survey. JAMA Cardiol. 2017;2(1):56\u201365.","journal-title":"JAMA Cardiol"},{"key":"1482_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2147\/CLEP.S104258","volume":"8","author":"AG O'Keeffe","year":"2016","unstructured":"O'Keeffe AG, Nazareth I, Petersen I. Time trends in the prescription of statins for the primary prevention of cardiovascular disease in the United Kingdom: a cohort study using the health improvement network primary care data. Clin Epidemiol. 2016;8:123\u201332.","journal-title":"Clin Epidemiol"},{"issue":"181","key":"1482_CR12","first-page":"130","volume":"2016","author":"Valentino M, Al Danaf J, Panakos A, Ragupathi L, Duffy D, Whellan D. Impact of the","year":"2013","unstructured":"Valentino M, Al Danaf J, Panakos A, Ragupathi L, Duffy D, Whellan D. Impact of the. American College of Cardiology\/American Heart Association cholesterol guidelines on the prescription of high-intensity statins in patients hospitalized for acute coronary syndrome or stroke. Am Heart J. 2013;2016(181):130\u20136.","journal-title":"Am Heart J"},{"issue":"5","key":"1482_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-014150","volume":"7","author":"HC Hsieh","year":"2017","unstructured":"Hsieh HC, Hsu JC, Lu CY. 10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan's National Health Insurance Research Database. BMJ Open. 2017;7(5):e014150.","journal-title":"BMJ Open"},{"key":"1482_CR14","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.atherosclerosis.2018.11.015","volume":"280","author":"JE Blais","year":"2019","unstructured":"Blais JE, Chan EW, Law SWY, Mok MT, Huang D, Wong ICK, Siu CW. Trends in statin prescription prevalence, initiation, and dosing: Hong Kong, 2004-2015. Atherosclerosis. 2019;280:174\u201382.","journal-title":"Atherosclerosis"},{"key":"1482_CR15","doi-asserted-by":"crossref","unstructured":"Lee H, Park JB, Hwang IC, Yoon YE, Park HE, Choi SY, et al. Association of four lipid components with mortality, myocardial infarction, and stroke in statin-naive young adults: a nationwide cohort study. Eur J Prev Cardiol. 2020:2047487319898571.","DOI":"10.1177\/2047487319898571"},{"key":"1482_CR16","volume-title":"Lipid Screening in Childhood for Detection of Multifactorial Dyslipidemia: A Systematic Evidence Review for the US Preventive Services Task Force. edn","author":"P Lozano","year":"2016","unstructured":"Lozano P, Henrikson NB, Morrison CC, Dunn J, Nguyen M, Blasi P, Whitlock EP. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. In: Lipid Screening in Childhood for Detection of Multifactorial Dyslipidemia: A Systematic Evidence Review for the US Preventive Services Task Force. edn. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016."},{"issue":"4","key":"1482_CR17","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10557-018-6810-1","volume":"32","author":"TN Harrison","year":"2018","unstructured":"Harrison TN, Scott RD, Cheetham TC, Chang SC, Hsu JY, Wei R, et al. Trends in statin use 2009-2015 in a large integrated health system: pre- and Post-2013 ACC\/AHA guideline on treatment of blood cholesterol. Cardiovasc Drugs Ther. 2018;32(4):397\u2013404.","journal-title":"Cardiovasc Drugs Ther"},{"key":"1482_CR18","unstructured":"Joint Committee for Developing Chinese guidelines on Prevention and Treatment of Dyslipidemia in Adults. [Chinese guidelines on prevention and treatment of dyslipidemia in adults (2016 Revised version)]. Chin J Circ. 2016;16(10):15\u201335."},{"issue":"6","key":"1482_CR19","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/clc.20514","volume":"32","author":"X Li","year":"2009","unstructured":"Li X, Xu Y, Li J, Hu D. The gender differences in baseline characteristics and statin intervention among outpatients with coronary heart disease in China: the China cholesterol education program. Clin Cardiol. 2009;32(6):308\u201314.","journal-title":"Clin Cardiol"},{"key":"1482_CR20","doi-asserted-by":"crossref","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J-C, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130\u20139.","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"issue":"1","key":"1482_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12872-018-0941-y","volume":"18","author":"N Laleman","year":"2018","unstructured":"Laleman N, Henrard S, van den Akker M, Goderis G, Buntinx F, Van Pottelbergh G, Vaes B. Time trends in statin use and incidence of recurrent cardiovascular events in secondary prevention between 1999 and 2013: a registry-based study. BMC Cardiovasc Disord. 2018;18(1):209.","journal-title":"BMC Cardiovasc Disord"},{"key":"1482_CR22","unstructured":"Weiwei C, Runlin G, Lisheng L, Zhu M, Wang W, Wang Y. China cardiovascular disease report 2017: a summary. Chin J Circ. 2018;1:1\u20138."},{"issue":"11","key":"1482_CR23","first-page":"e495","volume":"63","author":"F Brown","year":"2017","unstructured":"Brown F, Singer A, Katz A, Konrad G. Statin-prescribing trends for primary and secondary prevention of cardiovascular disease. Can Fam Physician. 2017;63(11):e495\u2013503.","journal-title":"Can Fam Physician"},{"issue":"17","key":"1482_CR24","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1001\/jama.2015.13766","volume":"314","author":"ED Kantor","year":"2015","unstructured":"Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States from 1999-2012. J Am Med Assoc. 2015;314(17):1818.","journal-title":"J Am Med Assoc"},{"issue":"1","key":"1482_CR25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/nyas.12150","volume":"1290","author":"J Tom\u00e9-Carneiro","year":"2013","unstructured":"Tom\u00e9-Carneiro J, Gonz\u00e1lvez M, Larrosa M, Y\u00e1\u00f1ez-Gasc\u00f3n MJ, Garc\u00eda-Almagro FJ, Ruiz-Ros JA, Tom\u00e1s-Barber\u00e1n FA, Garc\u00eda-Conesa MT, Esp\u00edn JC. Resveratrol in primary and secondary prevention of cardiovascular disease: a dietary and clinical perspective. Ann N Y Acad Sci. 2013;1290(1):37\u201351.","journal-title":"Ann N Y Acad Sci"},{"issue":"8","key":"1482_CR26","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s11739-017-1694-9","volume":"12","author":"BT Huang","year":"2017","unstructured":"Huang BT, Peng Y, Huang FY, Xia TL, Gui YY, Liao YB, et al. Trends in prescribing rate of statins at discharge and modifiable factors in patients with atherosclerotic cardiovascular disease. Intern Emerg Med. 2017;12(8):1121\u20139.","journal-title":"Intern Emerg Med"},{"key":"1482_CR27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1472-6904-7-14","volume":"7","author":"I Hartz","year":"2007","unstructured":"Hartz I, Sakshaug S, Furu K, Engeland A, Eggen AE, Njolstad I, Skurtveit S. Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption - an individual-level prescription database study. BMC Clin Pharmacol. 2007;7:14.","journal-title":"BMC Clin Pharmacol"},{"issue":"7554","key":"1482_CR28","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1136\/bmj.332.7554.1344","volume":"332","author":"JC Moon","year":"2006","unstructured":"Moon JC, Bogle RG. Switching statins. BMJ. 2006;332(7554):1344\u20135.","journal-title":"BMJ"},{"issue":"9","key":"1482_CR29","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1097\/MLR.0b013e3181e41bcb","volume":"48","author":"JE Martikainen","year":"2010","unstructured":"Martikainen JE, Saastamoinen LK, Korhonen MJ, Enlund H, Helin-Salmivaara A. Impact of restricted reimbursement on the use of statins in Finland: a register-based study. Med Care. 2010;48(9):761\u20136.","journal-title":"Med Care"},{"issue":"1","key":"1482_CR30","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1472-6963-14-6","volume":"14","author":"G Damiani","year":"2014","unstructured":"Damiani G, Federico B, Anselmi A, Silvestrini G, Iodice L, Navarra P, Cas RD, Raschetti R, Ricciardi W. The impact of Regional co-payment and National reimbursement criteria on statins use in Italy: an interrupted time-series analysis. BMC Health Serv Res. 2014;14(1):6\u20136.","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"1482_CR31","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/j.1365-2125.2007.02907.x","volume":"64","author":"S Sakshaug","year":"2010","unstructured":"Sakshaug S, Furu KO, Ronning M, Skurtveit S. Switching statins in Norway after new reimbursement policy: a nationwide prescription study. Br J Clin Pharmacol. 2010;64(4):476\u201381.","journal-title":"Br J Clin Pharmacol"},{"issue":"suppl 1","key":"1482_CR32","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1093\/eurheartj\/eht309.3689","volume":"34","author":"AK Gitt","year":"2013","unstructured":"Gitt AK, Juenger C, Smolka W, Wood D, Kastelein J. Impact of a budget-restrictive (Germany) versus an incentive-driven (UK) reimbursement system on LDL-goal-achievement in statin-treated patients for secondary prevention: results of DYSIS. Eur Heart J. 2013;34(suppl 1):3689.","journal-title":"Eur Heart J"},{"issue":"5","key":"1482_CR33","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1586\/erp.09.43","volume":"9","author":"B Godman","year":"2009","unstructured":"Godman B, Burkhardt T, Bucsics A, Wettermark B, Wieninger P. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future. Expert Rev Pharmacoecon Outcomes Res. 2009;9(5):475.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"9","key":"1482_CR34","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.amjmed.2011.02.012","volume":"124","author":"SS Virani","year":"2011","unstructured":"Virani SS, Steinberg L, Murray T, Negi S, Nambi V, Woodard LD, Bozkurt B, Petersen LA, Ballantyne CM. Barriers to non-HDL cholesterol goal attainment by providers. Am J Med. 2011;124(9):876\u201380 e872.","journal-title":"Am J Med"},{"issue":"1","key":"1482_CR35","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jacl.2012.06.004","volume":"7","author":"R Vijayakrishnan","year":"2013","unstructured":"Vijayakrishnan R, Kalyatanda G, Srinivasan I, Abraham GM. Compliance with the adult treatment panel III guidelines for hyperlipidemia in a resident-run ambulatory clinic: a retrospective data analysis. J Clin Lipidol. 2013;7(1):43\u20137.","journal-title":"J Clin Lipidol"},{"issue":"3","key":"1482_CR36","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jacc.2014.09.088","volume":"65","author":"RS Rosenson","year":"2015","unstructured":"Rosenson RS, Kent ST, Brown TM, Farkouh ME, Levitan EB, Yun H, et al. Underutilization of high-intensity statin therapy after hospitalization for CoronaryHeart disease. J Am Coll Cardiol. 2015;65(3):270\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1482_CR37","doi-asserted-by":"publisher","first-page":"914.e915","DOI":"10.1016\/j.amjmed.2015.02.013","volume":"128","author":"S Jam\u00e9","year":"2015","unstructured":"Jam\u00e9 S, Wittenberg E, Potter MB, Fleischmann KE. The new lipid guidelines: what do primary care clinicians think? Am J Med. 2015;128(8):914.e915\u20130.","journal-title":"Am J Med"},{"issue":"1","key":"1482_CR38","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1471-2296-10-24","volume":"10","author":"AB Elisabeth","year":"2009","unstructured":"Elisabeth AB, Denig P, Vliet TV, Dekker JH. Reasons of general practitioners for not prescribing lipid-lowering medication to patients with diabetes: a qualitative study. BMC Fam Pract. 2009;10(1):24.","journal-title":"BMC Fam Pract"},{"issue":"8","key":"1482_CR39","first-page":"434","volume":"9","author":"Q Huang","year":"2016","unstructured":"Huang Q, Grabner M, Sanchez RJ, Willey VJ, Cziraky MJ, Palli SR, Power TP. Clinical characteristics and unmet need among patients with atherosclerotic cardiovascular disease stratified by statin use. Am Health Drug Benefits. 2016;9(8):434\u201344.","journal-title":"Am Health Drug Benefits"},{"key":"1482_CR40","doi-asserted-by":"publisher","unstructured":"Olufade T, Zhou S, Anzalone D, Kern DM, Tunceli O, Cziraky MJ, Willey VJ. Initiation Patterns of Statins in the 2 Years After Release of the 2013 American College of Cardiology\/American Heart Association (ACC\/AHA) cholesterol management guideline in a large US health plan. J Am Heart Assoc. 2017;6(5):e005205. https:\/\/doi.org\/10.1161\/JAHA.116.005205.","DOI":"10.1161\/JAHA.116.005205"},{"issue":"1","key":"1482_CR41","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1177\/1060028015608199","volume":"50","author":"JF Zupec","year":"2016","unstructured":"Zupec JF, Marrs JC, Saseen JJ. Evaluation of statin prescribing for secondary prevention in primary care following new guideline recommendations. Ann Pharmacother. 2016;50(1):17\u201321.","journal-title":"Ann Pharmacother"},{"issue":"6","key":"1482_CR42","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.jacl.2016.09.010","volume":"10","author":"H Zhang","year":"2016","unstructured":"Zhang H, Plutzky J, Shubina M, Turchin A. Risk factors for lack of statin therapy in patients with diabetes and coronary artery disease. J Clin Lipidol. 2016;10(6):1406\u201313.","journal-title":"J Clin Lipidol"},{"key":"1482_CR43","doi-asserted-by":"crossref","unstructured":"Li XN, Xu HR, Chen WL, Chu NN, Zhu JR. Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study. Clin Ther. 2010;32(3):575\u201387.","DOI":"10.1016\/j.clinthera.2010.03.015"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-020-01482-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-020-01482-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-020-01482-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,24]],"date-time":"2021-04-24T23:20:06Z","timestamp":1619306406000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-020-01482-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,25]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1482"],"URL":"https:\/\/doi.org\/10.1186\/s12872-020-01482-5","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,25]]},"assertion":[{"value":"20 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in the present study were in line with the Ethics Committee of Jinshan Hospital. We declared that the study protocols were approved by the Ethics Committee of Jinshan Hospital.The present study retrospectively analyzed data abstracted from the hospital information system of Jinshan Hospital without interventions or disruptions to patients\u2019 lives, and no direct human participants were involved, thus informed consent was not required and waived by the Ethics Committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"201"}}